May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Tendency Towards Success in Retinopathy of Prematurity (ROP) Treatment
Author Affiliations & Notes
  • R. Bagdoniene
    Dept. of opthalmology, Vilnius university hospital, Vilnius, Lithuania
  • R. Sirtautiene
    Dept. of opthalmology, Vilnius university hospital, Vilnius, Lithuania
  • Footnotes
    Commercial Relationships  R. Bagdoniene, None; R. Sirtautiene, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4089. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Bagdoniene, R. Sirtautiene; Tendency Towards Success in Retinopathy of Prematurity (ROP) Treatment . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4089.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Abstract:
 

To evaluate the efficacy of ROP treatment during 9 years (1995–2003).

 

Modified cryo and laser–cryo therapy was used for treatment of ROP. During 1995–1997 years only cryotherapy was used. Since 1998 years laser +cryo therapy has been employed. All screening, treatment and postoperative follow up procedures have been performed by the same two specialists (authors of presentation). Anatomical outcome was evaluated at least 6 months after treatment.

 

Out of 2159 infants screened for ROP in Vilnius University Children's hospital 320 reached treshold and undervent treatment.

 

Zone 2 threshold ROP was diagnosed in 445 eyes. Zone 1 threshold ROP was detected in 182 eyes. Success and failure rate in each year is presented in table 1.

 

1. Since 1996 year 100% success is achieved in Zone 2 ROP treatment.

 

2. Gradually growing success rate is approaching to exellence in Zone 1 ROP treatment.

 

3. ROP is becoming entirely curable disease.

 

 

 
Keywords: retinopathy of prematurity • laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×